Copyright
©The Author(s) 2020.
World J Clin Oncol. Oct 24, 2020; 11(10): 836-843
Published online Oct 24, 2020. doi: 10.5306/wjco.v11.i10.836
Published online Oct 24, 2020. doi: 10.5306/wjco.v11.i10.836
Patient | Age | Sex | PS | Site | CT | Cycles (n) | RT dose | Response | Site ofrelapse | 2nd Line CT | Survival(mo) |
1 | 52 | F | 0 | Mid | CE | 6 | 50 Gy in 20 Fr | CR | Liver | 2 Top | 25 |
2 | 78 | F | 0 | Low | PE | 1 | 50 Gy in 20 Fr | CR | UK | None | 25 |
3 | 71 | M | 0 | Low | CE/PE | 3 | 50 Gy in 20 Fr | CR | Local | 6 PE | 23 |
4 | 70 | M | 1 | Low1 | PE | 5 | 50 Gy in 20 Fr | PR | Local | 2 PE | 20 |
5 | 67 | F | 1 | Low | CE | 4 | 45 Gy in 25 Fr | PR | Local2 | 3 ECX | 65.5 |
6 | 70 | F | 1 | Low | CE | 4 | 50 Gy in 20 Fr | UK | UK | None | 19 |
7 | 73 | F | 1 | Low | PE | 4 | 4005 cGy in 15 Fr | PR | UK | None | 17 |
8 | 69 | M | 1 | Low1 | PE | 5 | 50 Gy in 25 Fr | PR | UK | 2 PE | 20 |
- Citation: Alfayez M. Primary small cell oesophageal carcinoma: A retrospective study of different treatment modalities. World J Clin Oncol 2020; 11(10): 836-843
- URL: https://www.wjgnet.com/2218-4333/full/v11/i10/836.htm
- DOI: https://dx.doi.org/10.5306/wjco.v11.i10.836